我国乙型肝炎防治成就及机遇和挑战

Advances and challenge in prevention and treatment of hepatitis B in China

慢性乙型肝炎(简称乙肝)感染严重危害全球公众健康,我国曾是慢性乙肝高流行区。随着乙肝疫苗普遍接种政策的实施,我国人群中新发慢性乙肝病毒感染率已经大幅度降低。但现有慢性乙肝病毒感染人数仍然众多,相关疾病卫生经济负担仍重,患者知晓率、抗病毒治疗药物的可及性及规范抗病毒治疗率仍然很低。按照世界卫生组织制定的防控目标,通过政府、企业及学术界的共同努力,不断提高乙肝治疗药物的可及性和规范化治疗率,我国乙肝防治必将取得更大的成绩。

Chronic HBV infection is a serious public health problem worldwide including China where it was highly prevalent.Implementation of universal HBV vaccination in infants has led to a dramatic decrease in HBV prevalence.However,the huge number of persons with chronic HBV infection will still represent a significant burden to the public care system.The patients′awareness of their infection status,the accessibility and uptake of antiviral therapy are still poor.With the goal of 2030 set by World Health Organization,joint efforts of the public sectors,enterprise and medical community to improve the accessibility of antiviral drugs and standardized treatment,will achieve a greater achievement in the prevention and treatment of chronic hepatitis B in China.